284 related articles for article (PubMed ID: 17588358)
1. Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor.
George S
Curr Oncol Rep; 2007 Jul; 9(4):323-7. PubMed ID: 17588358
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
[TBL] [Abstract][Full Text] [Related]
3. Developments in targeted therapy of advanced gastrointestinal stromal tumors.
Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751
[TBL] [Abstract][Full Text] [Related]
4. Current and emerging pharmacological treatments for gastrointestinal stromal tumour.
Ganjoo KN; Patel S
Drugs; 2011 Feb; 71(3):321-30. PubMed ID: 21319869
[TBL] [Abstract][Full Text] [Related]
5. Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.
Kim EJ; Zalupski MM
J Surg Oncol; 2011 Dec; 104(8):901-6. PubMed ID: 22069175
[TBL] [Abstract][Full Text] [Related]
6. Current management of patients with gastrointestinal stromal tumor receiving the multitargeted tyrosine kinase inhibitor sunitinib.
Pilotte AP
Curr Med Res Opin; 2015; 31(7):1363-76. PubMed ID: 25912466
[TBL] [Abstract][Full Text] [Related]
7. Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype.
Judson IR
J Clin Oncol; 2008 Nov; 26(33):5322-5. PubMed ID: 18955449
[No Abstract] [Full Text] [Related]
8. Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.
Lee NR; Yhim HY; Yim CY; Kwak JY; Song EK
Ann Pharmacother; 2011 Oct; 45(10):e56. PubMed ID: 21954449
[TBL] [Abstract][Full Text] [Related]
9. Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series.
Rutkowski P; Magnan H; Chou AJ; Benson C
BMC Cancer; 2017 Nov; 17(1):717. PubMed ID: 29110655
[TBL] [Abstract][Full Text] [Related]
10. Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
Bauer S; Jones RL; Blay JY; Gelderblom H; George S; Schöffski P; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Su Y; Meade J; Wang T; Sherman ML; Ruiz-Soto R; Heinrich MC
J Clin Oncol; 2022 Dec; 40(34):3918-3928. PubMed ID: 35947817
[TBL] [Abstract][Full Text] [Related]
11. C-kit, GIST, and imatinib.
Siehl J; Thiel E
Recent Results Cancer Res; 2007; 176():145-51. PubMed ID: 17607922
[TBL] [Abstract][Full Text] [Related]
12. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib in the management of gastrointestinal stromal tumours (GISTs).
Hopkins TG; Marples M; Stark D
Eur J Surg Oncol; 2008 Aug; 34(8):844-850. PubMed ID: 18082353
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib: from rational design to clinical efficacy.
Chow LQ; Eckhardt SG
J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
[TBL] [Abstract][Full Text] [Related]
15. [Sunitinib as a second-line therapy for imatinib-resistant gastrointestinal stromal tumors].
Ishikawa T; Kanda T; Kosugi S; Yajima K; Hatakeyama K
Gan To Kagaku Ryoho; 2011 Jun; 38(6):916-21. PubMed ID: 21677482
[TBL] [Abstract][Full Text] [Related]
16. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
Reichardt P; Demetri GD; Gelderblom H; Rutkowski P; Im SA; Gupta S; Kang YK; Schöffski P; Schuette J; Soulières D; Blay JY; Goldstein D; Fly K; Huang X; Corsaro M; Lechuga MJ; Martini JF; Heinrich MC
BMC Cancer; 2016 Jan; 16():22. PubMed ID: 26772734
[TBL] [Abstract][Full Text] [Related]
17. Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies.
Wozniak A; Floris G; Debiec-Rychter M; Sciot R; Schöffski P
Cancer Invest; 2010 Oct; 28(8):839-48. PubMed ID: 20690803
[TBL] [Abstract][Full Text] [Related]
18. VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib.
Koh Y; Lee HE; Im SA; Kim SH; Kim TM; Han SW; Oh DY; Kim JH; Lee SH; Kim DW; Kim TY; Kim WH; Heo DS; Bang YJ
Diagn Mol Pathol; 2011 Sep; 20(3):143-7. PubMed ID: 21817899
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance.
Chen YY; Yeh CN; Cheng CT; Chen TW; Rau KM; Jan YY; Chen MF
World J Gastroenterol; 2011 Apr; 17(16):2113-9. PubMed ID: 21547131
[TBL] [Abstract][Full Text] [Related]
20. Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
von Mehren M
Clin Colorectal Cancer; 2006 Nov; 6 Suppl 1():S30-4. PubMed ID: 17419150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
